Inventor · disambiguated record
Jose F. Rojas
Also filed as: ROJAS JOSE · ROJAS JOSE F
13 granted patents·6 pending applications·53 citations·filing 2014–2024
89Inventor score
Files withREGENERON PHARMA19
Top patents by PatentIndex Score
19 records- 0197US9155290B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2014·Granted Oct 13, 2015·27 cites·4 claims
- 0295US9738897B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Aug 22, 2017·13 cites·29 claims
- 0393US9580715B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Feb 28, 2017·7 cites·30 claims
- 0487US10561125B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2017·Granted Feb 18, 2020·2 cites·6 claims
- 0587US2024229048A1Nuclease-mediated dna assemblyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0683US10626402B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2019·Granted Apr 21, 2020·1 cites·52 claims
- 0782US10273488B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2017·Granted Apr 30, 2019·1 cites·31 claims
- 0881US12369570B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·6 claims
- 0981US11111504B2Methods for scarless introduction of targeted modifications into targeting vectorsREGENERON PHARMA·Filed 2020·Granted Sep 7, 2021·1 cites·29 claims
- 1080US11470828B2Rodent model of mood disordersREGENERON PHARMA·Filed 2020·Granted Oct 18, 2022·1 cites·24 claims
- 1171US11932859B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2020·Granted Mar 19, 2024·0 cites·31 claims
- 1271US11503813B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2020·Granted Nov 22, 2022·0 cites·4 claims
- 1370US2023123787A1Rodent model of mood disordersREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1464US11499164B2Methods for scarless introduction of targeted modifications into targeting vectorsREGENERON PHARMA·Filed 2021·Granted Nov 15, 2022·0 cites·29 claims
- 1560US2015366175A1Humanized il-15 animalsREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 1659US12250931B2Genetically modified mouse with a humanized PNPLA3 gene and methods of useREGENERON PHARMA·Filed 2021·Granted Mar 18, 2025·0 cites·23 claims
- 1759US2025194571A1Compositions and methods for defining optimal treatment timeframes in lysosomal diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1853US2019141966A1Non-Human Animals Comprising SLC30A8 Mutation And Methods Of UseREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 1951US2019032156A1Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →